IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOF
This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.
1 . A method for delivering a formulation comprising an effective amount of octreotide to a subject, comprising: implanting an implantable device into the subject, wherein the implantable device comprises octreotide surrounded by a polyurethane-based polymer.
2 . The method of claim 1 , wherein the polyurethane-based polymer is selected from the group consisting of: a Tecophilic® polymer, a Tecoflex® polymer and a Carbothane® polymer.
3 . The method of claim 2 , wherein the polyurethane-based polymer is a Tecophilic® polymer with an equilibrium water content of at least about 24%.
4 . The method of claim 2 , wherein the polyurethane-based polymer is a Tecoflex® polymer with a flex modulus of about 2,300.
5 . A drug delivery device for the controlled release of octreotide over an extended period of time to produce local or systemic pharmacological effects, comprising:
a) a polyurethane-based polymer formed to define a hollow space; and
b) a solid drug formulation comprising octreotide and optionally one or more pharmaceutically-acceptable carriers,
wherein the solid drug formulation is in the hollow space, and wherein the device provides a desired release rate of octreotide from the device after implantation.
6 . The drug delivery device of claim 5 , wherein the drug delivery device is conditioned and primed under conditions chosen to match the water solubility characteristics of the at least one active agent.
7 . The drug delivery device of claim 6 , wherein the pharmaceutically-acceptable carrier is stearic acid.
8 . The drug delivery device of claim 7 , wherein the polyurethane-based polymer is selected from the group consisting of: a Tecophilic® polymer, a Tecoflex® polymer and a Carbothane® polymer.
9 . The drug delivery device of claim 8 , wherein the polyurethane-based polymer is a Tecophilic® polymer with an equilibrium water content of at least about 24%.
10 . The drug delivery device of claim 8 , wherein the polyurethane-based polymer is a Tecoflex® polymer with a flex modulus of about 2,300.
11 . The drug delivery device of claim 5 , wherein the appropriate conditioning and priming parameters can be selected to establish the desired delivery rates of the at least one active agent, wherein the priming parameters are time, temperature, conditioning medium and priming medium.